Sign in
LRMR Stock Price, Chart, Stats & News
Larimar Therapeutics, Inc.
Save
296.96M
Market cap
–
Current P/E
–
Forward P/E
LRMR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -113.60% |
ROE | -137.70% |
D/E | 0.05x |
Interest coverage ratio | – |
LRMR valuation
P/E | – |
P/S | – |
P/B | 5.04x |
P/CF | -3.48x |
P/FCF | -3.49x |
P/OCF | -3.48x |
PEG | 0.16x |
EV multiple | -2.80x |
About
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials.
Similar securities
Based on sector and market capitalization
Report issue